Monday, July 21, 2008

Missing memorial cross tears at man’s heart

Missing memorial cross tears at man’s heart
Newsdurhamregion.com - Durham,Ontario,Canada
I have diabetes and multiple sclerosis and have to use a cane when I walk. Dorothy was right there for me. Always. I miss her and Matt very, very much. ...
See all stories on this topic

Pfizer, Merck and Eli Lilly come together to launch a new company that will create technologies to speed drug development

By Edyta Zielinska

Tysabri/

Biogen Idec upgraded to buy at Merrill Lynch
Trading Markets (press release) - Los Angeles,CA,USA
Biogen is significantly undervalued, the firm said, given the expected growth that will be driven by acceleration of Biogen drug Tysabri in the treatment of ...
See all stories on this topic

Periodicals Wrap-Up for Monday, July 21st
istockAnalyst.com - Salem,OR,USA
Three years after it was recalled, Biogen Idec’s (BIIB) Tysabri, used to treat multiple sclerosis and Crohn’s disease, may now become a blockbuster seller, ...
See all stories on this topic

Biogen-Idec (BIIB): Upgraded to Buy at Merrill Lynch
StreetInsider.com (subscription) - Birmingham,MI,USA
Key near-term driversinclude better-than-expected Q2 earnings and a Tysabri/PML update, which they believe is likely to be favorable. ...
See all stories on this topic

Media Digest 7/21/2008 Reuters, WSJ, NYTimes, FT, Bloomberg
24/7 Wall St. - New York,NY,USA
The Wall Street Journal reports that Biogen's Tysabri, a drug for multiple sclerosis and Crohn's disease, is shaping up to be a blockbuster. ...
See all stories on this topic

Biogen Drug's Steady Return
Wall Street Journal - USA
By KEITH J. WINSTEIN Biogen Idec Inc. will mark two years this week the relaunch of Tysabri, a potent drug for multiple sclerosis and Crohn's disease that ...
See all stories on this topic

PRESS DIGEST - Wall Street Journal - July 21
Reuters - USA
Tysabri, a potent drug for multiple sclerosis and Crohn's disease, is shaping up for blockbuster status two years after its relaunch. ...
See all stories on this topic


Drug makers at loss for antidote to threat of generics, price ...
Edmonton Journal - Edmonton,Alberta,Canada
... Sanofi-Aventis SA and AstraZeneca Plc. Novartis's diversified business and promising new drugs like FTY720 for multiple sclerosis and meningitis ...
See all stories on this topic

Earnings Preview: Biogen Idec
Forbes - NY,USA
... or PPMS, during the quarter. The drug also failed to meet its goal in a late-stage lupus study, surprising Wall Street. Rituxan, which had sales of $651 ...
See all stories on this topic

Children's Early Cognitive Development Influenced By Family Resources, Parenting Quality
Even among low-income families, mothers with greater social and economic resources were more supportive in parenting their children than those with fewer resources, which in turn influenced the children's cognitive performance.
The image “http://www.msanswers.ca/App_Themes/AskTheExpert_English/Images/en_logoEN.gif” cannot be displayed, because it contains errors.The image “http://www.msanswers.ca/App_Themes/AskTheExpert_English/Images/question_buttonEN.gif” cannot be displayed, because it contains errors.

Treatment

Dr. Lee

Assistant Professor of Medicine (Neurology)
View BIO

Q :
Is there such a thing as "inactive" relapsing remitting MS (RRMS)? Is there ever a situation in which confirmed RRMS should not be treated with disease modifying drugs, assuming there are no problems with tolerating this medication?
A :
It is possible that a patient can have “inactive MS” and not have any relapses or progression. However, it is very hard for a physician to know which patient is in this category. If someone has had the disease for many years (and on no treatment), with very infrequent attacks (i.e. one mild attack every 10 yrs or so), one could argue this is inactive MS or benign disease. In these cases, I would not recommend disease modifying therapy. However, if a patient has infrequent attacks while they are on drug, it is hard to know if this is due to the natural history or because of the drug itself. In this situation, I would not recommend stopping the disease modifying therapy.
7/22/2008 12:44:43 AM
More answers from Dr. Liesly Lee
More answers in the category: Treatment


DISCLAIMER: Please be aware that this information does not necessarily represent the opinion of the MS Society of Canada, and is not intended as medical advice. For specific advice and opinion, always consult a physician.
© 2008 Multiple Sclerosis Society of Canada

Gene Variations May Predict Antidepressant Response
http://www.nlm.nih.gov/medlineplus/news/fullstory_67133.html
Got enough Vitamin D?
GoErie.com - Erie,PA,USA
By JOHN FAUBER MILWAUKEE -- A growing body of research suggests that inadequate vitamin D can substantially increase the risk of a variety of diseases, ...
See all stories on this topic

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home